Oncology
Refine search
Pharmaceutical
US pharma major Eli Lilly today announced positive top-line results from the Phase III LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. 16 February 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma today announced the appointment of three senior leaders to strengthen its late-stage development capabilities and preparation for commercial readiness. 16 February 2026
Pharmaceutical
US biotech Gilead Sciences has agreed a global licensing deal worth up to $1.5 billion with China’s Genhouse Bio for its synthetic lethal cancer candidate GH31. 16 February 2026
Pharmaceutical
Japan’s Ono Pharmaceutical today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible, second generation Bruton’s tyrosine kinase inhibitor (BTK), for the treatment of relapsed or refractory primary central nervous system lymphoma (R/R PCNSL). 16 February 2026
Biotechnology
Japanese drugmaker Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for Datroway (datopotamab deruxtecan) for the treatment of adult patients with hormone receptor negative and HER2 negative unresectable or recurrent breast cancer, a subtype commonly referred to as triple negative breast cancer (TNBC). 12 February 2026
Pharmaceutical
For the entire 2025 fiscal year, French drugmaker Ipsen’s revenues rose by 8.1%, or 10.9% at constant exchange rates, reaching a total of 3.68 billion euros ($4.37 billion). 12 February 2026
Biotechnology
Japan’s Chugai Pharmaceutical and Swiss ADC specialist Araris Biotech have announced that the Tokyo firm has exercised its option under the research collaboration and option to license agreement (RCO) that the companies signed last year. 12 February 2026
Pharmaceutical
Chugai starts 2026 having just celebrated its first century, just as Nicolas Henriot completes his first year leading Chugai Pharma Europe. It is a moment of symmetry that the new general manager says has sharpened the region’s sense of purpose, balancing a century of scientific heritage with a need for agility in a fast-moving European market. 12 February 2026
Biotechnology
US biotech Citius Oncology, the oncology-focused subsidiary of Citius Pharmaceuticals, has entered into an exclusive distribution agreement with Unipha, a leading international healthcare services company, to support access to Lymphir (denileukin diftitox-cxdl) outside the USA. 11 February 2026
Generics
UK specialty generics company Aspire Pharma has acquired Caragen, an Ireland-based pharmaceutical organization with a strong presence in hospital immunology therapies. 11 February 2026
Biotechnology
Swedish biotech Neogap Therapeutics, which is developing personalized cancer immunotherapy using the patient’s own cells, has raised 87 million Swedish kronor ($9.8 million) in a financing round led by Nordic investment company Sciety. 11 February 2026
Biotechnology
Anglo-Swedish drugmaker AstraZeneca has announced a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Imfinzi (durvalumab), a perioperative treatment regimen for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). 10 February 2026
Pharmaceutical
British pharma major AstraZeneca has reported fourth-quarter revenue of $15.5 billion, up 4%, with reported earnings per share of $1.50, a 55% increase. Core EPS was $2.12, broadly flat year on year. 10 February 2026
Biotechnology
Immuno-oncology and inflammation startup Kainova Therapeutics has announced the successful first close of its Series B financing round totaling $32 million CAD ($23.6 million). 10 February 2026
Pharmaceutical
Iambic, a US clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with Japan’s Takeda. 10 February 2026
article
US biotech Eikon Therapeutics has raised about $381 million in the largest biotech IPO of the year so far, but the market’s first reaction was cautious. Shares fell nearly 17% on their first day of trading, closing at $15. 6 February 2026
Biotechnology
Chinese biotech Kelun-Biotech has won a new approval from China’s National Medical Products Administration for sac-TMT (sacituzumab tirumotecan), a TROP2-directed antibody-drug conjugate. 6 February 2026
Biotechnology
California, USA-based Coherus Oncology has entered into a clinical supply agreement with JUS healthcare giant Johnson & Johnson to evaluate tagmokitug (CHS-114). 5 February 2026
Biotechnology
Pennsylvania, USA-based Third Arc Bio, a biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, has announced the closing of a $52 million series A extension. 4 February 2026
Pharmaceutical
US pharma major Eli Lilly was trading 9% higher in Wednesday’s early trading after announcing its financial results for the fourth-quarter of 2025 and providing 2026 financial guidance. 4 February 2026
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Biotechnology
Chinese clinical-stage biotech OriCell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110 million. 13 April 2026
Biotechnology
US biotech Replimune has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower and casting doubt over the program’s future. 13 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze